EyeBrain, an Ivry-sur-Seine, France-based developer of markers of cerebral function for neurological and psychiatric disorders and diseases, raised €1.3m (approximately $1.47m) in funding.
Backers included existing shareholders, the Fonds Régional de Co-Investissement d’Ile-de-France (FRCI, regional joint investment fund for the Ile-de-France or Greater Paris area) and the Anaxago crowdfunding platform. The FRCI has an exclusive partnership with the crowndfunding platform.
The company intends to use the funds to continue the development of its diagnostic products for neurological and psychiatric disorders such as attention deficit hyperactivity disorder (ADHD) and schizophrenia and to boost its sales presence in Europe.
Founded in 2008 and led by Serge Kinkingnéhun, CEO, EyeBrain develops markers of cerebral function for neurological and psychiatric disorders and diseases and learning disorders. By recording and analyzing the movement of the eye using the company’s algorithms, they enable the analysis of eye movement behavior and the testing of specific regions of the brain. In 20 minutes, the devices can provide an additional diagnosis with quantifiable results.
EyeBrain previously raised €1.2m ($1.36m) in 2009 from funds managed by CapDecisif Management and from investment fund G1JIDF, then €3.3m ($3.74m) in 2012 from historical investors and Octalfa, Sudinnova and CM-CIC Capital Innovation.